For the first time in Medicare's 61-year history, Part D will cover GLP-1 medications like Wegovy and Zepbound for weight loss when the obesity indication becomes billable on July 1, 2026. The policy mechanism that makes this financially viable is something most patients have never heard of: the CMS Balance Model. It is the payment framework that lets Medicare afford brand-name GLP-1 drugs without blowing a hole through the Part D trust fund — and whether you qualify for it determines what you will actually pay this summer.
If you are a Part D enrollee with a BMI of 30 or higher, or 27 with a qualifying comorbidity, this is the most important Medicare policy shift of the decade. Here is exactly how the Balance Model works, who qualifies, and what you need to do before July.
What Is the CMS Balance Model?
The Balance Model is a value-based payment pilot developed by the Center for Medicare and Medicaid Innovation (CMMI), the experimental arm of CMS created under the Affordable Care Act. Unlike traditional Medicare Part D — which pays a fixed negotiated rate regardless of patient outcomes — the Balance Model ties drug reimbursement directly to clinical performance. Manufacturers get paid more when patients achieve measurable outcomes (weight loss percentages, A1C reductions, cardiovascular events avoided), and less when they do not.
For GLP-1 medications, that means Novo Nordisk and Eli Lilly will be paid based on whether enrollees actually lose weight and stay on therapy — not just on how many prescriptions get filled. CMS has framed the model as a way to afford category-level coverage for expensive chronic-condition drugs that would otherwise be budget-impossible under standard fee-for-service Part D. Final rules are still subject to CMS finalization in the coming weeks, but the structural framework is locked in.
The Balance Model is legally distinct from the Inflation Reduction Act's Medicare drug price negotiation program, though both policies are pushing toward the same outcome: lower costs for high-spend drugs.
Which GLP-1 Medications Does Balance Model Cover in 2026?
The Balance Model is narrow. It applies specifically to GLP-1s prescribed for the obesity indication — not diabetes. That distinction matters.
Wegovy (semaglutide 2.4mg) — Covered under Balance Model for the obesity indication. Novo Nordisk's flagship weight loss injection is the anchor product in the pilot.
Zepbound (tirzepatide) — Covered under Balance Model for obesity. Eli Lilly's dual GIP/GLP-1 agonist is the second pillar of the program.
Ozempic and Mounjaro — Still covered under traditional Part D for their type 2 diabetes indications. These are not part of the Balance Model because their diabetes use was already a covered benefit under the original Part D statute.
Foundayo (orforglipron) — Pending inclusion. Eli Lilly's oral GLP-1 pill was FDA-approved on April 1, 2026 and is expected to be added to the Balance Model formulary alongside its $50/month Bridge Program access later this year.
Separately, CMS is running a transitional $50/month Bridge Program (July to December 2026) that caps patient out-of-pocket costs for qualifying Part D enrollees while the full Balance Model rollout gets underway in January 2027.
Medicare GLP-1 Bridge Program 2026: How It Works
The Bridge Program is the patient-facing piece of the policy. It runs from July 1, 2026 through December 31, 2026, and caps out-of-pocket costs at $50 per month for eligible Part D enrollees filling a qualifying GLP-1 prescription for obesity.
Eligibility requirements:
- Enrollment in a Medicare Part D prescription drug plan (standalone or through Medicare Advantage Part D) - Body mass index of 30 or higher, OR 27 or higher with at least one weight-related comorbidity - Qualifying comorbidities include hypertension, obstructive sleep apnea, dyslipidemia, and type 2 diabetes - Prescribing physician documentation of obesity diagnosis (ICD-10 E66.x) in your medical record
Prior authorization: Yes. Each Part D plan will require a prior auth form signed by your prescriber attesting to BMI, comorbidity status, and that lifestyle modification has been attempted. Plans have been instructed to process these within 72 hours once the benefit goes live.
What happens after December 2026: The $50 cap expires. Standard Part D cost-sharing kicks in — which, under the Inflation Reduction Act, includes a $2,000 annual out-of-pocket maximum starting in 2026. In practice, that means a Wegovy or Zepbound prescription will hit your OOP max quickly, then run at $0 for the rest of the year. The full Balance Model launches January 2027 with new cost-sharing structures that CMS has not yet finalized.
Who Qualifies for Medicare Balance Model GLP-1 Coverage?
You qualify if all three of the following apply:
First, you are enrolled in Medicare Part D — either as a standalone drug plan layered on Original Medicare, or as part of a Medicare Advantage plan that includes drug coverage. Dual-eligible beneficiaries (Medicare plus Medicaid) are covered under separate rules that vary by state.
Second, you meet the BMI and comorbidity threshold: BMI 30+, or BMI 27+ with hypertension, sleep apnea, dyslipidemia, type 2 diabetes, or another documented weight-related condition.
Third, you are not in an exclusion category. Current exclusions include gestational obesity, active treatment for certain cancers, medullary thyroid carcinoma history, and multiple endocrine neoplasia syndrome type 2.
To apply, contact your Part D plan directly starting in June 2026. Most plans are building dedicated GLP-1 enrollment portals that will go live 2-4 weeks before the July 1 start date. You will need your prescriber to submit the prior authorization packet on your behalf.
Cost Breakdown: What You'll Actually Pay
Through December 2026 (Bridge Program): $50/month out-of-pocket, period. No deductible reset surprises, no coinsurance tier shifting.
Compared to cash price: Wegovy's list price is approximately $1,350/month. Zepbound runs $1,060/month list. The Bridge program is an 96% discount off list for Wegovy and 95% off for Zepbound.
Savings card interaction: Here is a critical catch. Under CMS rules, manufacturer savings cards cannot stack with Medicare Part D benefits. If you have been using Novo Nordisk's WegovyCare savings card or Eli Lilly's Zepbound savings card, you will need to stop using them once you enter the Balance Model or Bridge Program. This is a longstanding CMS anti-kickback policy, not a new rule.
Post-2026: The full Balance Model rolls out January 2027. CMS has signaled that cost-sharing will remain affordable — likely in the $35-75/month range depending on plan — but final numbers are subject to finalization.
Timeline: Key Dates for Medicare GLP-1 Coverage 2026-2027
- June 2026 — Part D plans open GLP-1 prior authorization portals - July 1, 2026 — Bridge Program goes live, $50/month cap begins - October 2026 — Medicare Open Enrollment; compare Part D plans for 2027 GLP-1 coverage - December 31, 2026 — Bridge Program sunsets - January 1, 2027 — Full CMS Balance Model launches with permanent value-based pricing - Mid-2027 — First outcomes data from Balance Model enrollees reviewed by CMMI
What To Do Next
If you are on Medicare Part D and think you qualify, the single most valuable thing you can do right now is schedule an appointment with your primary care provider to document your BMI and any qualifying comorbidities in your medical record. That documentation is what your Part D plan will review when processing your prior authorization in June or July.
For a deeper breakdown of Medicare GLP-1 coverage timelines and plan-by-plan details, read our [Medicare GLP-1 2026 coverage guide](/cost/medicare-glp1-2026). To compare drug-specific costs, see our [Wegovy cost analysis](/cost/wegovy) and [Zepbound cost analysis](/cost/zepbound). And for the 5 things every eligible American should prepare before July, read our [Medicare Bridge Program preparation guide](/blog/medicare-glp1-bridge-what-to-know).
CMS's Balance Model is not a finished policy — it is a pilot that will be studied, tweaked, and either scaled or scaled back based on 2027 outcomes data. But for the millions of Medicare enrollees who have been priced out of GLP-1 therapy, July 1 is the day the door finally opens.